NCT07123727View on ClinicalTrials.gov

A Study to Examine Anktiva for the Treatment of COVID-19.

PHASE2RecruitingINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

September 4, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions

Long COVIDLong COVID SyndromeLong Covid 19

Interventions

DRUG

Anktiva

600ug of NAI administered subcutaneously

Trial Locations (1)

90245

RECRUITING

Chan Soon-Schiong Institute for Medicine (CSSIFM), El Segundo

Sponsors

Lead Sponsor

ImmunityBio, Inc.

All Listed Sponsors

lead

ImmunityBio, Inc.

INDUSTRY

NCT07123727 - A Study to Examine Anktiva for the Treatment of COVID-19. | Biotech Hunter | Biotech Hunter